GRL-0617

Source: Wikipedia, the free encyclopedia.
GRL-0617
Identifiers
  • 5-amino-2-methyl-N-[(1R)-1-naphthalen-1-ylethyl]benzamide
JSmol)
  • CC1=C(C=C(C=C1)N)C(=O)N[C@H](C)C2=CC=CC3=CC=CC=C32
  • InChI=1S/C20H20N2O/c1-13-10-11-16(21)12-19(13)20(23)22-14(2)17-9-5-7-15-6-3-4-8-18(15)17/h3-12,14H,21H2,1-2H3,(H,22,23)/t14-/m1/s1
  • Key:UVERBUNNCOKGNZ-CQSZACIVSA-N

GRL-0617 is a drug which is one of the first compounds discovered that acts as a selective small-molecule inhibitor of the protease enzyme papain-like protease (PLpro) found in some human pathogenic viruses, including the coronavirus SARS-CoV-2. It has been shown to inhibit viral replication in silico [1] and in vitro.[2][3][4][5]

See also

References